Cohance Lifesciences gets nod to make $10 million investment in NJ Bio Inc

03 Dec 2025 Evaluate

Cohance Lifesciences has received approval for the fund infusion by way of investment in compulsorily convertible preferred stock of NJ Bio Inc, USA, a subsidiary of the company, upto an amount of $10 million. The fund when deployed will be used by the said subsidiary to support its growth initiatives including capex.

The board of directors of the company in its meeting held on December 02, 2025 considered and approved the same.

Cohance Lifesciences (Formerly, Suven Pharmaceuticals) is a leading CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commercialization.

Cohance Lifesciences Share Price

543.10 -6.00 (-1.09%)
05-Dec-2025 12:04 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1805.00
Dr. Reddys Lab 1280.00
Cipla 1521.35
Zydus Lifesciences 933.80
Lupin 2100.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×